Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 and Fulvestrant with or without HS-10352 in advanced breast cancer
NCT06788197Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Mar 2025
- Primary completion
- Mar 2028
- Modality
- Small Molecules
01
Overview
Phase 2 trial of HS-10352 in breast cancer (2 arms), sponsored by Henan Cancer Hospital. Primary endpoints: Objective Response Rate and Recommended Phase 2 dose at 28 days. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
HS-10352
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06788197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06788197.